Human TNFAIP3 knockout HeLa cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
Human TNFAIP3 knockout HeLa cell lysate suitable for WB. View our extensive range of validated lysates from normal and diseased human, mouse and rat tissue.
View Alternative Names
AISBL, MGC104522, MGC138687, MGC138688, OTU domain-containing protein 7C, OTUD7C, Putative DNA-binding protein A20, TNAP3_HUMAN, TNF alpha-induced protein 3, TNFA1P2, TNFAIP3 (A20), Tumor necrosis factor alpha-induced protein 3, Tumor necrosis factor induced protein 3, Tumor necrosis factor inducible protein A20, Zinc finger protein A20
- WB
Unknown
Western blot - Human TNFAIP3 knockout HeLa cell lysate (AB257112)
Lane 1 : Wild-type HeLa cell lysate (20 μg)
Lane 2 : TNFAIP3 knockout HeLa cell lysate (20 μg)
Lane 3 : Jurkat cell treated with 5ng/ml PMA for 48 hours and then treated with 2μg/ml PHA for 48 hours, whole cell lysate (20 μg)
Lane 4 : Untreated Jurkat cell lysate (20 μg)
Lanes 1-4 : Merged signal (red and green). Green - ab92324 observed at 80 kDa. Red - loading control, ab8245 observed at 37 kDa.
ab92324 Anti-TNFAIP3 antibody [EPR2663] was shown to specifically react with TNFAIP3 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265983 (knockout cell lysate ab257112) was used. Wild-type and TNFAIP3 knockout samples were subjected to SDS-PAGE. ab92324 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-TNFAIP3 antibody [EPR2663] (<a href='/en-us/products/primary-antibodies/tnfaip3-antibody-epr2663-ab92324'>ab92324</a>) at 1/1000 dilution
Lane 1:
Wild-type HeLa cell lysate at 20 µg
Lane 2:
TNFAIP3 knockout HeLa cell lysate at 20 µg
Lane 3:
Jurkat cell treated with 5ng/ml PMA for 48 hours and then treated with 2µg/ml PHA for 48 hours, whole cell lysate at 20 µg
Lane 4:
Untreated Jurkat cell lysate at 20 µg
Predicted band size: 89 kDa
Observed band size: 80 kDa
false
- WB
Supplier Data
Western blot - Human TNFAIP3 knockout HeLa cell lysate (AB257112)
Lane 1 : Wild-type HeLa cell lysate (20 μg)
Lane 2 : TNFAIP3 knockout HeLa cell lysate (20 μg)
Lane 3 : Jurkat cell treated with 5ng/ml PMA for 48 hours and then treated with 2μg/ml PHA for 48 hours, whole cell lysate (20 μg)
Lane 4 : Untreated Jurkat cell lysate (20 μg)
Lanes 1-4 : Merged signal (red and green). Green - ab13597 observed at 80 kDa. Red - loading control, ab181602 observed at 37 kDa.
ab13597 Anti-TNFAIP3 antibody [59A426] was shown to specifically react with TNFAIP3 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265983 (knockout cell lysate ab257112) was used. Wild-type and TNFAIP3 knockout samples were subjected to SDS-PAGE. ab13597 and Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-TNFAIP3 antibody [59A426] (<a href='/en-us/products/primary-antibodies/tnfaip3-antibody-59a426-ab13597'>ab13597</a>) at 1/500 dilution
Lane 1:
Wild-type HeLa cell lysate at 20 µg
Lane 2:
TNFAIP3 knockout HeLa cell lysate at 20 µg
Lane 3:
Jurkat cell treated with 5ng/ml PMA for 48 hours and then treated with 2µg/ml PHA for 48 hours, whole cell lysate at 20 µg
Lane 4:
Untreated Jurkat cell lysate at 20 µg
Predicted band size: 89 kDa
Observed band size: 80 kDa
false
- Sanger seq
Unknown
Sanger Sequencing - Human TNFAIP3 knockout HeLa cell lysate (AB257112)
Homozygous : 1 bp insertion in exon7
Reactivity data
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com